Kite’s Yescarta and Tecartus therapies show promise
Objective response rate and complete response rates were encouraging for both treatments
Read More
Tag: Kite
Kite and Refuge Biotechnologies to work together to research blood cancer
The licence agreement bolsters Kite’s expertise in synthetic biology for oncology
Read More
Kite’s Yescarta to receive European marketing authorisation
First treatment in 30 years to improve second-line treatment of DLBCL
Read More
Kite’s CAR T therapy Tecartus authorised in EU for MCL
CHMP backed the CAR T cell therapy for the treatment of mantle cell lymphoma back in October
Read More
Kite files second CAR-T therapy with US regulators
A submission in the EU is expected early next year
Read More
NICE OKs NHS funding for Gilead’s CAR T-cell therapy
Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma.
Read More
CAR-T therapy could be available to NHS patients this year
NHS England chief executive Simon Stevens has indicated that chimeric antigen receptor T-cell therapy (CAR-T) could be available on the NHS this year, offering eligible patients a ‘ground-breaking’ approach to treating cancer.
Read More
Gilead links with Sangamo in gene therapy alliance
Gilead’s Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer.
Read More
US approves second CAR-T therapy
Gilead’s Yescarta – recently acquired through its purchase of Kite Pharma – has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.
Read More
Gilead buys into CAR-T with $11.9bn deal for Kite
Gilead Sciences is buying Kite Pharma in a deal worth $11.9 billion, securing itself access to the latter’s experimental CAR-T therapy axicabtagene ciloleucel and wider cancer pipeline.
Read More
Kite first to submit CAR-T therapy in Europe
Kite Pharma has submitted the first CAR-T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin lymphoma (NHL).
Read More
Novartis gets speedy review for CAR-T cell therapy
Novartis has stepped ahead in the race to get the first cancer-killing CAR-T cell therapy on the market having successfully filed a biologics license application with US regulators.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
